U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Area of Science:

• Gynecologic Oncology
• Regulatory Science
• Drug Development

Background:

• Significant advancements in gynecologic cancer treatment have occurred over the past decade.
• The therapeutic landscape for these cancers is rapidly evolving.

Purpose of the Study:

• To summarize U.S. Food and Drug Administration (FDA) drug approvals for gynecologic cancers from 2010 to 2020.
• To outline endpoints, trial design, results, and regulatory considerations for 17 new indications.

Main Methods:

• Review of FDA approval data for gynecologic cancers between 2010 and 2020.
• Analysis of approval types (accelerated vs. regular), primary efficacy endpoints, and regulatory pathways.

Main Results:

• Seventeen new indications were approved: 6 accelerated approvals (AA) and 11 regular approvals (RA).
• Three of the six AAs have converted to RA, with ongoing trials for the remaining three.
• Approvals were based on progression-free survival (n=10), objective response rate (n=6), and overall survival (n=1), demonstrating a favorable benefit-risk profile.

Conclusions:

• The period saw substantial FDA regulatory activity in gynecologic oncology drug development.
• FDA initiatives like priority review and novel pathways are shaping cancer drug approvals.
• Ongoing research is crucial for converting accelerated approvals to regular approvals and confirming long-term benefits.